These two do not work the same way and do not ask the same thing of you. Sofwave sends ultrasound through skin that stays intact. Morpheus8 pushes needles through the skin and delivers radiofrequency heat below the surface.
That shows up as downtime. Sofwave is usually redness and mild swelling for hours to about a day. For RF microneedling, one published study puts downtime at three to four days, and in a series of 40 patients redness occurred in every one of them and swelling in about 30%.
The clearest difference is on paper. Sofwave's FDA clearance names real cosmetic uses. Morpheus8's clearance names none — it is cleared for electrocoagulation and hemostasis, and since 2023 for procedures "where coagulation/contraction of soft tissue or hemostasis is needed." Wrinkles, acne scars, jawline and double chin appear nowhere in it.
That difference is regulatory, not a verdict on results. A 510(k) clearance means a device was judged substantially equivalent to an earlier one. It is not proof that a benefit was demonstrated.
Seven parallel transducers fire together. Its original 2021 clearance used Ultherapy as its predicate device, in the same FDA product category that Ultherapy's De Novo created.
An array of insulated pins carries 1 MHz bipolar RF into the skin. Morpheus8 is InMode's Fractora platform, renamed and extended with deeper, insulated needles.
Ultrasound at 10 to 12 MHz warms a continuous band of the mid dermis. The transducers are parallel and non-focused, so the energy spreads across a band instead of concentrating at one deep point. Contact cooling protects the surface.
Needles carry current into the dermis. Manufacturer manuals state the pins are coated with insulation except the distal 0.5 mm, so heat is deposited at the tip and the top layer of skin is largely spared.
Sofwave is a mid-dermal device. Despite similar marketing language, it does not work at the deep plane Ultherapy is aimed at, which is 4.5 mm.
Manufacturer labelling lists 1 to 4 mm for the 12-pin Prime tip and up to 7 mm for the 24- and 40-pin tips. The deepest figure in any FDA summary is 7.0 mm.
As of April 2025 (K250146): to improve facial lines and wrinkles, lift the eyebrow, and lift lax submental and neck tissue in people aged 22 and over; short-term improvement in the appearance of cellulite; treatment of acne scars; and improvement in the appearance of skin laxity on the upper arms.
K192695, December 2019: electrocoagulation and hemostasis. K231790, July 2023: procedures "where coagulation/contraction of soft tissue or hemostasis is needed." Above 62 mJ per pin, the applicator is limited to Fitzpatrick skin types I to IV.
Atrophic acne scars are the best-evidenced use of RF microneedling as a class.
This is the conventional description, not a figure from FDA labelling.
One published study of RF microneedling of the lower face and neck describes downtime of three to four days. In a separate series of 40 patients, redness occurred in all of them and swelling in about 30%.
Conventional description, not labelling.
Manufacturer labelling says 1 to 6 treatments, generally 3 to 5, repeated every 3 to 6 weeks. Published trial protocols cluster around 3 sessions.
Almost no published study used Morpheus8. The RF microneedling literature runs on Lutronic Genius and Infini, Jeisys, Pollogen, Lumenis and unnamed devices. A PubMed search for "Morpheus8" returns 16 records in total, several of them in industry-sponsored journal supplements, and no randomised controlled trial of Morpheus8 was found. Anyone searching for Morpheus8 results is being shown evidence produced on different equipment.
The evidence also runs out at six months. The longest properly measured follow-up in the RF microneedling literature is six months after the final treatment. A critical review of 42 higher-quality studies (Tan and colleagues, 2021) concluded that remodelling is slow and progressive and "continue[s] to improve even 6 months after treatment" — that is a statement about six months, not about durability at one to three years. The "one to three years" figure clinics often quote has no published source.
In the FDA's MAUDE postmarket database between January 2013 and October 2025, there were 114 reports of RF microneedling complications containing 224 events. Fat loss accounted for 26 of them, or 11.6% of reported events — the third most reported category, after textural changes and pigmentary change.
Read that number carefully. MAUDE is a voluntary reporting database with no denominator. It is a proportion of reports, not a rate among treated patients, and it cannot be turned into a per-patient risk.
There is evidence pointing the other way too. Wu and colleagues (2024) measured the submental fat layer by ultrasound in 30 patients treated with RF microneedling and found no significant change; the paper is titled "…without Lipolysis." The plausible reconciliation is that this is depth and energy dependent, and Morpheus8's selling point is precisely its ability to reach subdermal depths. Sofwave works at 1 to 2 mm in the dermis and is not a subcutaneous device.